MDACC Study No:2013-0569 ( NCT No: NCT01881789)
Title:Phase Ib/2, Multicenter, Open-Label Study of Oprozomib and Dexamethasone in Combination With Lenalidomide or Oral Cyclophosphamide in Patients with Newly Diagnosed Multiple Myeloma
Principal Investigator:Jatin J. Shah
Treatment Agent:Cyclophosphamide; Dexamethasone; Lenalidomide; oprozomib
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of oprozomib that can be given in combination with lenalidomide (Revlimid) and
dexamethasone or cyclophosphamide and dexamethasone to patients with MM. The
safety of oprozomib will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I/Phase II
Treatment Agents:Cyclophosphamide
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Onyx Therapeutics
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jatin J. Shah
Dept:Cancer Medicine
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults